Oslo, Norway, April 7, 2022 - Lytix Biopharma AS (Lytix), a clinical-stage
company with an in situ vaccination technology platform targeting cancer
indications, announces that it has published its Annual Report for 2021, which
was approved by the board of directors on April 6, 2022.

"Cancer remains one of the world's most challenging health issues. Affecting
people of all ages, cultures and lifestyles, this devastating illness represents
the second most common cause of death globally. At Lytix, we have bold ambitions
and are dedicated to being part of tomorrow's cancer treatment by overcoming a
major challenge in current immunotherapy. 

"We are confident that our innovative platform technology will address tumor
heterogeneity, that if not addressed, leads to recurrence of the cancer and
often even more therapy-resistant disease. Excitingly, our technology has
potentially broad applicability across solid tumors and has the potential to be
an integral part of future combination therapies," said Øystein Rekdal, CEO of
Lytix Biopharma.

The Annual Report for 2021 is attached to this notice and is also available on
the company's website, www.lytixbiopharma.com, under Investors. 


For further information please contact: 
Øystein Rekdal (CEO), 
Telephone: +47 975 73 358 
E-mail: Oystein.Rekdal@lytixbiopharma.com

About Lytix Biopharma AS
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company
developing novel cancer immunotherapies, an area within cancer therapy that is
aimed at activating the patient's immune system to fight cancer. The Company's
technology is based on pioneering research in "host defense peptides" - nature's
first line of defense towards foreign pathogens. Lytix Biopharma's lead product,
LTX-315, is a first-in-class oncolytic molecule representing a new and superior
in situ therapeutic vaccination principle to boost anti-cancer immunity, with
the potential to be the ideal combination partner with other types of
immunotherapies. LTX-315 target cancer cells and disintegrate their cell
membranes, causing immunogenic cell death and release of a patient's tumor
specific antigens. This mode of action allows cytotoxic T cells to recognize,
infiltrate, and attack cancer cells. The Company was admitted to trading on
Euronext Growth in Oslo in June 2021, following a private placement covered by
investors such as PBM Capital, a U.S. based, healthcare-focused investment firm.
For more information, visit www.lytixbiopharma.com.

About in situ vaccination 
In situ vaccination stimulates a patient's immune system by injecting drugs,
with the ability to kill cancer cells, straight into the tumor. Lytix Biopharma
has applied this approach with its first-in-class oncolytic molecules,
representing an alternative and unique approach to cancer vaccination.
Importantly, this approach generates an immune response against a broad antigen
repertoire without pre-identifying the antigens.